Association between Pre-miR-3131 rs57408770 and Pri-miR-34b/c rs4938723 Gene Polymorphisms and the Risk of Non-Hodgkin Lymphoma

authors:

avatar Reza Bahari , * , avatar mahsa poorjangi , avatar Seyed Mehdi Hashemi , avatar Masoomeh Bahari , avatar mohsen taheri ORCID

Koomesh: Vol.25, issue 2; 160-166
published online: August 07, 2023
article type: Research Article
received: May 09, 2022
accepted: May 07, 2023

how to cite: Bahari R, poorjangi M, Hashemi S M, Bahari M, taheri M. Association between Pre-miR-3131 rs57408770 and Pri-miR-34b/c rs4938723 Gene Polymorphisms and the Risk of Non-Hodgkin Lymphoma. koomesh. 2023;25(2):e152814. 

Abstract

Introduction: Lymphoma is the seventh most common malignancy worldwide, which is divided into types of neoplasms, of which three types, Hodgkin's lymphoma (HL), Non-Hodgkin's lymphoma (NHL), and Burkitt's lymphoma are the most common. miRNAs are regulators of gene expression that are involved in physiological processes and are involved in cancer. In the present study, the polymorphisms of pre-miR-3131 rs57408770 and Pri-miR-34b/c rs4938723 genes in patients with Non-Hodgkin's lymphoma were compared with healthy controls. Materials and Methods: In this case-control study, 359 specimens were studied, of which 173 were (NHL) patients and 186 were healthy controls. Patients were selected from the patients referred to the cancer clinic of Ali Ibn Abi Talib Hospital. The DNA genome was extracted from the peripheral blood sample by the salting out method. The variants of Pri-mir-34b/c rs4938723 and pre-miR-3131 rs57408770 genotypes were analyzed by PCR-RFLP method. Results: The results showed that Pri-miR-34b/c rs4938723 homozygous polymorphism increased the risk of (NHL) in codominant and Recessive models. (OR= 2.70, 95% CI =1.13-4.43, P=0.025, OR=2.91, CI 95% =1.17-7.42, P=0.018 respectively). Pre-miR-3131 rs57408770 polymorphism increased the risk of (NHL) in homozygous states in codominant and recessive models. (OR=2.26, 95% CI=1.21-4.25, P=0.006, respectively). Conclusion: The results showed a significant relationship between pre-miR-3131 rs57408770 polymorphism, Pri-miR-34b / c rs4938723, and (NHL) disease in the Iranian population.

References

  • 1.

    Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin 2015; 65: 5-29.

  • 2.

    Segel GB, Lichtman MA. Familial (inherited) leukemia, lymphoma, and myeloma: an overview. Blood Cells Mol Dis 2004; 32: 246-261.

  • 3.

    Jaffe ES, Harris NL, Stein H, Vardiman JW. World health organization classification of tumours: pathology and genetics, tumours of hematopoietic and lymphoid tissues. Lyon, France: IARC Press; 2001. ISBN 978-92-832-2411-2.##.

  • 4.

    Swerdlow S, Campo E, Harris N. World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC Press; 2008. ISBN. 978-92-832-2431-0.

  • 5.

    Chihara D, Nastoupil LJ, Williams JN, Lee P, Koff JL, Flowers CR. New insights into the epidemiology of non-Hodgkin lymphoma and implications for therapy. Exp Rev Anticancer Ther 2015;15: 1-14.

  • 6.

    Novelli S, Briones J, Sierra J. Epidemiology of lymphoid malignancies: last decade up-date. Springerplus 2013; 2: 70.

  • 7.

    Fouladseresht H, Ghorbani M, Hassanipour S, Delam H, Mokhtari A, Mohseni S, et al. The incidence of Non-Hodgkin Lymphoma in Iran: a systematic re-view and meta-analysis. World Cancer Res J 2019; 6.

  • 8.

    Zhang Q, Pu R, Du Y, Han Y, Su T, Wang H, Cao G. Non-coding RNAs in hepatitis B or C-associated hepatocellular carcinoma: potential diagnostic and prognostic markers and therapeutic targets. Cancer Lett 2012; 321: 1-12.

  • 9.

    Calin GA, Sevignani C, Dumitru CD, Hyslop T, Noch E, Yendamuri S, et al. Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci 2004; 101: 2999-3004.

  • 10.

    Feitelson MA, Lee J. Hepatitis B virus integration, fragile sites, and hepatocarcinogenesis. Cancer Lett 2007; 252: 157-170.

  • 11.

    Ni Y, Meng L, Wang L, Dong W, Shen H, Wang G, Liu Q, Du J. MicroRNA-143 functions as a tumor suppressor in human esophageal squamous cell carcinoma. Gene 2013; 517: 197-204.

  • 12.

    Esquela-Kerscher A, Slack FJ. Oncomirs-microRNAs with a role in cancer. Nature Rev Cancer 2006; 6: 259-269.

  • 13.

    Yang M, Liu R, Sheng J, Liao J, Wang Y, Pan E, et al. Differential expression profiles of microRNAs as potential biomarkers for the early diagnosis of esophageal squamous cell carcinoma. Oncol Rep 2013; 29: 169-176.

  • 14.

    Matsushima K, Isomoto H, Yamaguchi N, Inoue N, Machida H, Nakayama T, et al. MiRNA-205 modulates cellular invasion and migration via regulating zinc finger E-box binding homeobox 2 expression in esophageal squamous cell carcinoma cells. J Translat Med 2011; 9: 30.

  • 15.

    Corney DC, Hwang CI, Matoso A, Vogt M, Flesken-Nikitin A, Godwin AK, et al. Frequent downregulation of miR-34 family in human ovarian cancers. Clin Cancer Res 2010; 16: 1119-1128.

  • 16.

    Chen X, Hu H, Guan X, Xiong G, Wang Y, Wang K, et al. CpG island methylation status of miRNAs in esophageal squamous cell carcinoma. Int J Cancer 2012; 130: 1607-1613.

  • 17.

    Mazar J, Khaitan D, DeBlasio D, Zhong C, Govindarajan SS, Kopanathi S, et al. Epigenetic regulation of microRNA genes and the role of miR-34b in cell invasion and motility in human melanoma. PLoS One 2011; 6: e24922.

  • 18.

    Suzuki H, Yamamoto E, Nojima M, Kai M, Yamano HO, Yoshikawa K, et al. Methylation-associated silencing of microRNA-34b/c in gastric cancer and its involvement in an epigenetic field defect. Carcinogenesis 2010; 31: 2066-2073.

  • 19.

    Kubo T, Toyooka S, Tsukuda K, Sakaguchi M, Fukazawa T, Soh J, et al. Epigenetic silencing of microRNA-34b/c plays an important role in the pathogenesis of malignant pleural mesothelioma. Clin Cancer Res 2011; 17: 4965-4974.

  • 20.

    Corney DC, Flesken-Nikitin A, Godwin AK, Wang W, Nikitin AY. MicroRNA-34b and MicroRNA-34c are targets of p53 and cooperate in control of cell proliferation and adhesion-independent growth. Cancer Res 2007; 67: 8433-8438.

  • 21.

    Math E, Nguyen GH, Funamizu N, He P, Moake M, Croce CM, Hussain SP. Inflammation regulates microRNA expression in cooperation with p53 and nitric oxide. Int J Cancer 2012; 131: 760-765.

  • 22.

    Jain AK, Barton MC. Unmet expectations: miR-34 plays no role in p53-mediated tumor suppression in vivo. PLoS Genet 2012; 8: e1002859.

  • 23.

    Hou W, Tian Q, Zheng J, Bonkovsky HL. MicroRNA-196 represses Bach1 protein and hepatitis C virus gene expression in human hepatoma cells expressing hepatitis C viral proteins. Hepatology 2010; 51: 1494-1504.

  • 24.

    Wang C, Li L, Yin Z, Zhang Q, Zhao H, Tao R, et al. An indel polymorphism within pre-mir3131 confers risk for hepatocellular carcinoma. Carcinogenesis 2017; 38: 168-176.

  • 25.

    Hashemi M, Bahari G, Sattarifard H, Narouie B. Evaluation of a 3 base pair indel polymorphism within pre microRNA 3131 in patients with prostate cancer using mismatch polymerase chain reaction restriction fragment length polymorphism. Mol Clin Oncol 2017; 7: 696-700.

  • 26.

    Wang FJ, Ding Y, Mao YY, Jing FY, Zhang ZY, Jiang LF, et al. Associations between hsa-miR-603 polymorphism, lifestyle-related factors and colorectal cancer risk. Cancer Biomark 2014; 14: 225-231.

  • 27.

    Tong N, Chu H, Wang M, Xue Y, Du M, et al. Pri-miR-34b/c rs4938723 polymorphism contributes to acute lymphoblastic leukemia susceptibility in Chinese children. Leuk Lymphoma 2016; 57: 1436-1441.

  • 28.

    Sanaei S, Hashemi M, Rezaei M, Hashemi SM, Bahari G, Ghavami S. Evaluation of the pri-miR- 34b/c rs4938723 polymorphism and its association with breast cancer risk. Biomed Rep 2016; 5: 125-129.

  • 29.

    Zhang S, Qian J, Cao Q, Li P, Wang M, Wang J, et al. A potentially functional polymorphism in the promoter region of miR-34b/c is associated with renal cell cancer risk in a Chinese population. Mutagenesis 2014; 29: 149-154.

  • 30.

    Xu Y, Liu L, Liu J, Zhang Y, Zhu J, Chen J, et al. A potentially functional polymorphism in the promoter region of miR-34b/c is associated with an increased risk for primary hepatocellular carcinoma. Int J Cancer 2011; 128: 412-417.

  • 31.

    Zhang J, Huang X, Xiao J, Yang Y, Zhou Y, Wang X, et al. Pri-miR-124 rs531564 and pri-miR-34b/c rs4938723 polymorphisms are associated with decreased risk of esophageal squamous cell carcinoma in Chinese populations. PLoS One 2014; 9: e100055.

  • 32.

    Ji TX, Zhi C, Guo XG, Zhou Q, Wang GQ, Chen B, Ma FF. MiR-34b/c rs4938723 polymorphism significantly decreases the risk of digestive tract cancer: metaanalysis. Asian Pac J Cancer Prev 2015; 16: 6099-6104.

  • 33.

    Bensen JT, Tse CK, Nyante SJ, Barnholtz-Sloan JS, Cole SR, Millikan RC. Association of germline microRNA SNPs in pre-miRNA flanking region and breast cancer risk and survival: the Carolina Breast Cancer Study. Cancer Causes Control 2013; 24: 1099-1109.

  • 34.

    Son MS, Jang MJ, Jeon YJ, Kim WH, Kwon CI, Ko KH, et al. Promoter polymorphisms of pri-miR-34b/c are associated with hepatocellular carcinoma. Gene 2013; 524: 156-160.

  • 35.

    Yi DH, Wang BG, Zhong XP, Liu H, Liu YF. Pri-miR-34b/c rs4938723 TC heterozygote is associated with increased cancer risks: evidence from published data. Tumour Biol 2014; 35: 11967-11975.

  • 36.

    Pan XM, Sun RF, Li ZH, Guo XM, Qin HJ, Gao LB. Pri-miR-34b/c rs4938723polymorphism is associated with a decreased risk of gastric cancer. Genet Test Mol Biomark 2015; 19: 198-202.

  • 37.

    Lin Z, Chen L, Song M, Shi KQ, Tang KF. Association between a polymorphism in miR-34b/c and susceptibility to cancer-a meta-analysis. Asian Pac J Cancer Prev 2014; 15: 7251-7255.

  • 38.

    Chen P, Sun R, Pu Y, Bai P, Yuan F, Liang Y, et al. Pri-mir-34b/C and Tp-53 polymorphisms are associated with the susceptibility of papillary thyroid carcinoma: a case-control study. Medicine (Baltimore) 2015; 94: e1536.

  • 39.

    Liu Q, Yang G, Song XL, Wang Z, Shi G. Association between rs4938723 functional polymorphism in the promoter region of miR-34b/c gene and cancer risk. Clin Res Hepatol Gastroenterol 2015; 39: 526-533.

  • 40.

    Yuan F, Sun R, Chen P, Liang Y, Ni S, Quan Y, et al. Combined analysis of pri-miR-34b/c rs4938723 and TP53 Arg72Pro with cervical cancer risk. Tumour Biol 2016; 37: 6267-6273.

  • 41.

    Zhu J, Yang L, You W, Cui X, Chen Y, Hu J, et al. Genetic variation in miR-100 rs1834306 is associated with decreased risk for esophageal squamous cell carcinoma in Kazakh patients in northwest China. Int J Clin Exp Pathol 2015; 8: 7332-7340.